Drug Trial Radar · NCT07339267
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Jan 20, 2026
Primary completion
Oct 31, 2028
Study completion Oct 31, 2028
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jan 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, ASP5541 will be given to Chinese men with prostate cancer. It will be given together with prednisone and androgen deprivation therapy (ADT). Prednisone is a steroid, and ADT is already given to the men as their standard of care for prostate cancer. The main aims of the study are to check the safety of ASP5541, when given with prednisone and ADT, and to check how ASP5541 moves through the bodies of Chinese men. The men will receive ASP5541 as an injection into a muscle (intramuscular injection) at the side of the hip. They will all receive the same dose of ASP5541. The men will be given prednisone and ADT according to their label. The men will continue to receive ASP5541 with prednisone and ADT until their cancer gets worse or the doctor decides the men should stop study treatment.
Conditions
- Prostate Cancer
- Metastatic Castration-Resistant Prostate Cancer
- Metastatic Hormone Sensitive Prostate Cancer
Interventions
ASP5541Drug
Intramuscular injection
PrednisoneDrug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK) of Abiraterone Decanoate in Plasma: Maximum Concentration (Cmax)Time frame: Up to 6 months
- PK of Abiraterone Decanoate in Plasma: Time to Maximum Concentration (Tmax)Time frame: Up to 6 months
- PK of Abiraterone Decanoate in Plasma: Area Under the Curve from Time 0 to the Time of the Last Measurable Concentration (AUClast)Time frame: Up to 6 months
- PK of Abiraterone Decanoate in Plasma: Area Under the Concentration Time Curve from the Time of Dose Extrapolated to Time Infinity (AUCinf)Time frame: Up to 6 months
- PK of Abiraterone in Plasma: Maximum Concentration (Cmax)Time frame: Up to 6 months
- PK of Abiraterone in Plasma: Time to Maximum Concentration (Tmax)Time frame: Up to 6 months
- PK of Abiraterone in Plasma: Area Under the Curve from Time 0 to the Time of the Last Measurable Concentration (AUClast)Time frame: Up to 6 months
- PK of Abiraterone in Plasma: Area Under the Concentration Time Curve from the Time of Dose Extrapolated to Time Infinity (AUCinf)Time frame: Up to 6 months
- Number of Participants with Adverse Events (AEs)Time frame: Up to 33 months
- Number of Participants with Laboratory Value Abnormalities and/or AEsTime frame: Up to 31 months
- Number of Participants with Electrocardiogram (ECG) Abnormalities and/or AEsTime frame: Up to 31 months
- Number of Participants with Vital Sign Abnormalities and/or AEsTime frame: Up to 31 months
- Number of Participants with Physical Exam Abnormalities and/or AEsTime frame: Up to 31 months
- Number of Participants at Each Grade of Eastern Cooperative Oncology Group (ECOG) Performance Status ScoreTime frame: Up to 31 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.